Trial shows colchicine halves risk of MI
Doctors from Perth's Sir Charles Gairdner Hospital presented findings to the American Heart Association Scientific Sessions in Los Angeles today from a study of more than 500 patients with stable CAD.
The anti-inflammatory drug colchicine has long been registered to relieve pain in acute gout. But advancements in thinking about the inflammatory nature of coronary artery disease prompted Dr Peter Thompson and his colleagues to take an educated guess about the potential of the drug.
"We have done a clinical trial with this drug and we have found that when you administer this on a steady, low-dose basis in people with coronary heart disease, you can actually halve heart attack risk," Dr Thompson told AAP from Los Angeles.
"So far it is only a smallish trial but it looks very exciting and interesting. We went to this one [colchicine] knowing that it was a very likely candidate, and the results are very satisfying,” he said.